Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

ments within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; o
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Russia,s ... The Pharma 2020 Strategy provides incentives for local producers ... and foreign markets. These trends, however, were affected by ... following political and economic sanctions imposed on ... Russia responded to the ...
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... Sept. 16, 2014 Based on its ... Frost & Sullivan recognises Incisive Surgical with the ... Value Leadership. Incisive Surgical,s uniquely-designed, innovative INSORB® Absorbable ... eliminates the need for patients to undergo the ... removal  that may result in increased pain, wound ...
Breaking Medicine Technology:Global Medicines for Russia 2Global Laparoscopy Devices Industry Report 2014 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5
(Date:9/16/2014)... For patients with locally advanced pancreatic cancer, the ... may be a promising treatment option, ultimately allowing ... be an option, according to research presented today ... 56th Annual Meeting. , Surgery is the only ... adenocarcinoma (PDA), the most common type of pancreatic ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
(Date:9/16/2014)... September 16, 2014 Cloud based ... Streaming (HLS) & UStream API’S to serve m3u8 streams ... feature for broadcasting live video events with hundreds of ... , The App Builder is known for making beautiful ... iOS, BlackBerry and Windows 8 and already over 100,000 ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
(Date:9/16/2014)... workers die in motor vehicles than any other workplace ... to address at an international conference being hosted by ... Queensland (CARRS-Q). , The Occupational Safety in Transport Conference ... September 18 and 19 brings together experts from all ... mining to improve workplace health and safety. , CARRS-Q ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:A heart-felt need for dairy food 2Health News:CARRS-Q Host International Transport Safety Conference 2
... ... AZ (Vocus) December 23, 2008 -- Adding to a growing body of ... the December 23rd issue of Circulation further emphasized the need to exercise ... most Americans fall far short of the minimum recommended guidelines of physical ...
... Center for Clinical and Translational Science (CCTS) has ... third annual pilot-project grant program. The grants, which ... early studies in translational science that, if successful, ... CCTS, established through funds from a 2006 Clinical ...
... dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay News) ... in the United States combine over-the-counter medications with prescription ... potentially dangerous interactions, a new survey finds. , A ... more than 175,000 emergency department visits for adverse drug ...
... sports such as swimming had greater bone density in menopause ... exercise during adolescence may help women maintain their bone strength ... Dec. 22 in the British Journal of Sports Medicine ... the teenage exercise habits of 46 postmenopausal women, now aged ...
... perihepatic capsules with concomitant pelvic inflammation. The pain ... main symptom. These cases have to be cautiously ... is pain in the right upper abdomen Fitz-Hugh-Curtis ... that can be diagnosed by non-invasive methoids and ...
... presenting cells (APCs) that both initiate and modulate the ... antigen capture and presentation to T cells, with the ... T cells. Gastric cancer is one of the most ... progress, it is still difficult to treat advanced gastric ...
Cached Medicine News:Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:What is the clinical character of Fitz-Hugh-Curtis syndrome? 2Health News:A new light on tumor immunotherapy for gastric cancer 2
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Cardiac Markers Plus Control is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: